



TECHNICAL BULLETIN



Extended Drug Stability - Bupivacaine, Lidocaine, and Ropivacaine

Bupivacaine, Lidocaine and Ropivacaine were each stored in ON-Q pumps for thirty days at room temperature. Each drug was tested for stability by an outside laboratory (SCI – Los Angeles, CA). The following summarizes the results of this testing:

Drug/Concentrations Tested

Bupivacaine HCL Injection - 0.25%, 0.5%
Sensorcaine- MPF, AstraZeneca

Lidocaine HCL Injection, preservative free – 1%
Xylocaine-MPF, AstraZeneca

Ropivacaine HCL Injection – 0.2%
AstraZeneca

Procedure

Bupivacaine (0.25% and 0.5%), Lidocaine (1%) and Ropivacaine (0.2%) were stored in ON-Q pumps for thirty days at room temperature. A sample of each drug was also stored in a glass vial as a control. Ultraviolet spectroscopy was utilized to analyze the samples.

Summary of Results

With all three drugs, there were no significant differences between preparations stored in the pumps compared to the control sample.

Test results confirm that Bupivacaine (0.25% and 0.5%), Lidocaine (1%), and Ropivacaine (0.2%) are stable for up to thirty days when stored at room temperature in ON-Q pumps.

Please contact the Clinical Services Department at 800.448.3569 or 949-206-2700 if you have any questions regarding this information.

© ON-Q is a registered trademark of I-Flow Corporation.